Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-27T00:56:04.005Z Has data issue: false hasContentIssue false
  • English
  • Français

Uso de olanzapina en un paciente con esquizofrenia y riesgo de diabetes

Published online by Cambridge University Press:  12 May 2020

V. Folnegović-Smalc ,
V. Jukić ,
O. Kozumplik ,
N. Mimica  and
S. Uzun
V. Folnegović-Smalc
Affiliation:
Departamento Universitario de Psiquiatría, Hospital Psiquiátrico Vrapce, Bolnicka cesta 32, 10090Zagreb, Croacia
V. Jukić
Affiliation:
Departamento Universitario de Psiquiatría, Hospital Psiquiátrico Vrapce, Bolnicka cesta 32, 10090Zagreb, Croacia
O. Kozumplik
Affiliation:
Departamento Universitario de Psiquiatría, Hospital Psiquiátrico Vrapce, Bolnicka cesta 32, 10090Zagreb, Croacia
N. Mimica
Affiliation:
Departamento Universitario de Psiquiatría, Hospital Psiquiátrico Vrapce, Bolnicka cesta 32, 10090Zagreb, Croacia
S. Uzun
Affiliation:
Departamento Universitario de Psiquiatría, Hospital Psiquiátrico Vrapce, Bolnicka cesta 32, 10090Zagreb, Croacia
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

EsquizofreniaOlanzapinaDiabetes
Type
Caso clínico
Information
European Psychiatry (Ed. Española) , Volume 11 , Issue 3 , April 2004 , pp. 197 - 199
Copyright
Copyright © European Psychiatric Association 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

Allison, D.B., Mentore, J.L., Heo, M., Chandler, L.P., Cappelari, J.C., Infante, M.C., et al. Antipsychotic induced weight gain: a comprehensiva research synthesis. Am J Psychiatry 1999; 156:1686–96.Google ScholarPubMed
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): APA; 1994.Google Scholar
Henderson, D.C.Atypical antipsychotic—induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002;16(2):77–89.CrossRefGoogle ScholarPubMed
Lindenmayer, J.P., Nathan, A.M., Smith, R.C.Hyperglycemia associated with the use o f atypical antipsychotics. J Clin Psychiatry 2001;62(23):30–8.Google Scholar
Mir, S., Taylor, D.Atypical antipsychotics and hyperglycemia. Int Clin Psychopharmacol 2001; 16(2): 63–73.CrossRefGoogle Scholar
Rigalleau, V., Gatta, B., Bounaud, S., Masson, M., Bourgeois, M.L., Vergnot, V., et al. Diabetes as a result of atypical antipsychotic drugs—a report of three cases. Diabet Med 2000;17(ó):484–6.CrossRefGoogle ScholarPubMed
Rockwell, W.J.K., Ellinwood, E.H., Trader, D.W.Psychotropic drugs promoting weight gain: health risk and treatment implications. South Med J 1983;76:1407–12.CrossRefGoogle Scholar
Schatzberg, A.F., Nemeroff, C.B.Textbook of psychopharmacology. Washington (DC): American Psychiatric Press; 1998.Google Scholar
Wirshing, D.A., Spellberg, B.J., Erhart, S.M., Marder, S.R., Wirshing, W.C.Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44(8):778–83.CrossRefGoogle ScholarPubMed